|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-7-23
|
|
pubmed:abstractText |
Two recombinant IFN-beta products have been approved for the treatment of multiple sclerosis, a glycosylated form with the predicted natural amino acid sequence (IFN-beta-1a) and a non-glycosylated form that has a Met-1 deletion and a Cys-17 to Ser mutation (IFN-beta-1b). The structural basis for activity differences between IFN-beta-1a and IFN-beta-1b, is determined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0724-8741
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
641-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9587963-Adjuvants, Immunologic,
pubmed-meshheading:9587963-Antiviral Agents,
pubmed-meshheading:9587963-Base Sequence,
pubmed-meshheading:9587963-Cardiovirus Infections,
pubmed-meshheading:9587963-Cell Division,
pubmed-meshheading:9587963-Cell Line,
pubmed-meshheading:9587963-Cysteine,
pubmed-meshheading:9587963-Encephalomyocarditis virus,
pubmed-meshheading:9587963-Glycosylation,
pubmed-meshheading:9587963-Humans,
pubmed-meshheading:9587963-Interferon-beta,
pubmed-meshheading:9587963-Major Histocompatibility Complex,
pubmed-meshheading:9587963-Molecular Sequence Data,
pubmed-meshheading:9587963-Mutation,
pubmed-meshheading:9587963-Recombinant Proteins,
pubmed-meshheading:9587963-Serine
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).
|
|
pubmed:affiliation |
Biogen, Inc., Cambridge, Massachusetts 02142, USA. LauraRunkel@Biogen.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
